<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27821885</article-id><article-id pub-id-type="pmc">5096351</article-id><article-id pub-id-type="publisher-id">BLT.16.169524</article-id><article-id pub-id-type="doi">10.2471/BLT.16.169524</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Hepatitis B immunization for indigenous adults, Australia</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Vaccination des adultes autochtones contre l'h&#x000e9;patite&#x000a0;B, Australie</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Inmunizaci&#x000f3;n contra la hepatitis B para adultos ind&#x000ed;genas en Australia</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x0062a;&#x00648;&#x00641;&#x0064a;&#x00631; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00636;&#x0062f; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637;&#x000a0;" <bold>B </bold>" &#x00644;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646;&#x000a0;&#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646;&#x000a0;&#x00641;&#x0064a;&#x000a0;&#x00623;&#x00633;&#x0062a;&#x00631;&#x00627;&#x00644;&#x0064a;&#x00627; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x04e3a;&#x06fb3;&#x05927;&#x05229;&#x04e9a;&#x0571f;&#x08457;&#x06210;&#x05e74;&#x04eba;&#x063a5;&#x079cd;&#x04e59;&#x0809d;&#x075ab;&#x082d7;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x00412;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x0044f; &#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0043e;&#x00433;&#x0043e; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00410;&#x00432;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430; &#x00412;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Andre Louis Wattiaux et al.</alt-title><alt-title alt-title-type="title-running-head">Hepatitis B virus immunization, Australia</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Wattiaux</surname><given-names>Andre Louis</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>J Kevin</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Beard</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wesselingh</surname><given-names>Steve</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cowie</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Macartney</surname><given-names>Kristine</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label>National Centre for Immunisation Research and Surveillance, Kerry Packer Building, Children&#x02019;s Hospital at Westmead, corner Hawkesbury Rd and Hainsworth St, Westmead NSW 2145, <country>Australia</country>.</aff><aff id="aff2"><label>b</label>South Australian Health and Medical Research Institute, Adelaide, <country>Australia</country>.</aff><aff id="aff3"><label>c</label>WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, Melbourne, <country>Australia</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Andre Louis Wattiaux (email: <email xlink:href="andrewattiaux@yahoo.co.uk">andrewattiaux@yahoo.co.uk</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>16</day><month>9</month><year>2016</year></pub-date><volume>94</volume><issue>11</issue><fpage>826</fpage><lpage>834A</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2016</year></date><date date-type="rev-recd"><day>28</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>(c) 2016 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To quantify the disparity in incidence of hepatitis B between indigenous and non-indigenous people in Australia, and to estimate the potential impact of a hepatitis B immunization programme targeting non-immune indigenous adults.</p></sec><sec><title>Methods</title><p>Using national data on persons with newly acquired hepatitis B disease notified between 2005 and 2012, we estimated incident infection rates and rate ratios comparing indigenous and non-indigenous people, with adjustments for underreporting. The potential impact of a hepatitis B immunization programme targeting non-immune indigenous adults was projected using a Markov chain Monte Carlo simulation model.</p></sec><sec><title>Findings</title><p>Of the 54&#x000a0;522 persons with hepatitis B disease notified between 1&#x000a0;January 2005 and 31&#x000a0;December 2012, 1953 &#x000a0;infections were newly acquired. Acute hepatitis B infection notification rates were significantly higher for indigenous than non-indigenous Australians. The rates per 100&#x000a0;000 population for all ages were 3.6 (156/4&#x000a0;368&#x000a0;511) and 1.1 (1797/168&#x000a0;449&#x000a0;302) for indigenous and non-indigenous people respectively. The rate ratio of age-standardized notifications was 4.0 (95% confidence interval: 3.7&#x02013;4.3). If 50% of non-immune indigenous adults (20% of all indigenous adults) were vaccinated over a 10-year programme a projected 527&#x02013;549 new cases of acute hepatitis B would be prevented.</p></sec><sec><title>Conclusion</title><p>There continues to be significant health inequity between indigenous and non-indigenous Australians in relation to vaccine-preventable hepatitis B disease. An immunization programme targeting indigenous Australian adults could have considerable impact in terms of cases of acute hepatitis B prevented, with a relatively low number needed to vaccinate to prevent each case.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Quantifier les disparit&#x000e9;s entre les populations autochtones et non autochtones d'Australie en ce qui concerne l'incidence de l'h&#x000e9;patite&#x000a0;B et estimer l'impact potentiel d'un programme de vaccination contre l'h&#x000e9;patite&#x000a0;B destin&#x000e9; aux adultes autochtones non immunis&#x000e9;s.</p></sec><sec><title>M&#x000e9;thodes</title><p>&#x000c0; l'aide des donn&#x000e9;es nationales sur les nouveaux cas d'h&#x000e9;patite&#x000a0;B signal&#x000e9;s entre 2005 et 2012, nous avons estim&#x000e9; le taux d'incidence ainsi que les ratios des taux pour les personnes autochtones et les non autochtones et les avons compar&#x000e9;s, en proc&#x000e9;dant &#x000e0; des ajustements pour tenir compte des sous-signalements. L'impact potentiel d'un programme de vaccination contre l'h&#x000e9;patite&#x000a0;B destin&#x000e9; aux adultes autochtones non immunis&#x000e9;s a &#x000e9;t&#x000e9; d&#x000e9;termin&#x000e9; &#x000e0; l'aide d'un mod&#x000e8;le de simulation de Monte Carlo par cha&#x000ee;nes de Markov.</p></sec><sec><title>R&#x000e9;sultats</title><p>Sur les 54&#x000a0;522&#x000a0;cas d'h&#x000e9;patite&#x000a0;B signal&#x000e9;s entre le 1er&#x000a0;janvier 2005 et le 31&#x000a0;d&#x000e9;cembre 2012, 1953 concernaient des personnes qui avaient r&#x000e9;cemment contract&#x000e9; la maladie. Le taux de signalement des h&#x000e9;patites&#x000a0;B aigu&#x000eb;s &#x000e9;tait nettement plus &#x000e9;lev&#x000e9; pour les Australiens autochtones que pour les non autochtones. Le taux pour 100&#x000a0;000&#x000a0;habitants, tous &#x000e2;ges confondus, &#x000e9;tait respectivement de 3,6 (156/4&#x000a0;368&#x000a0;511) et de 1,1 (1797/168&#x000a0;449&#x000a0;302) pour les autochtones et les non autochtones. Le ratio des taux de signalement standardis&#x000e9;s selon l'&#x000e2;ge &#x000e9;tait de 4,0 (intervalle de confiance de 95%: 3,7-4,3). Si 50% des adultes autochtones non immunis&#x000e9;s (soit 20% de l'ensemble des adultes autochtones) &#x000e9;taient vaccin&#x000e9;s, dans le cadre d'un programme sur 10&#x000a0;ans, 527 &#x000e0; 549 nouveaux cas d'h&#x000e9;patite&#x000a0;B aigu&#x000eb; pourraient &#x000ea;tre &#x000e9;vit&#x000e9;s.</p></sec><sec><title>Conclusion</title><p>D'importantes in&#x000e9;galit&#x000e9;s sanitaires persistent entre les Australiens autochtones et non autochtones en ce qui concerne l'h&#x000e9;patite&#x000a0;B &#x000e9;vitable par la vaccination. Un programme de vaccination destin&#x000e9; aux adultes autochtones pourrait avoir un impact consid&#x000e9;rable sur la pr&#x000e9;vention des cas d'h&#x000e9;patite&#x000a0;B aigu&#x000eb;, avec un nombre relativement faible de personnes &#x000e0; vacciner pour &#x000e9;viter l'apparition de nouveaux cas.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Cuantificar la desigualdad en la incidencia de hepatitis B entre personas ind&#x000ed;genas y no ind&#x000ed;genas de Australia y estimar el posible impacto de un programa de inmunizaci&#x000f3;n contra la hepatitis B dirigido a adultos ind&#x000ed;genas no inmunes.</p></sec><sec><title>M&#x000e9;todos</title><p>Mediante el uso de informaci&#x000f3;n nacional sobre personas reci&#x000e9;n diagnosticadas con hepatitis B entre 2005 y 2012, se estimaron tasas de infecci&#x000f3;n incidental y coeficientes de tasas comparando a personas ind&#x000ed;genas y no ind&#x000ed;genas, con ajustes para la ausencia informativa. Se estim&#x000f3; el posible impacto de un programa de inmunizaci&#x000f3;n contra la hepatitis B dirigido a adultos ind&#x000ed;genas no inmunes utilizando un modelo de simulaci&#x000f3;n de Montecarlo basado en las cadenas de Markov.</p></sec><sec><title>Resultados</title><p>De las 54&#x000a0;522 personas con hepatitis B registradas entre el 1 de enero de 2005 y el 31 de diciembre de 2012, se adquirieron 1&#x000a0;953 nuevos contagios. Las tasas de registro de contagio de hepatitis B aguda fueron mucho mayores entre la poblaci&#x000f3;n australiana ind&#x000ed;gena que entre la no ind&#x000ed;gena. Las tasas por cada 100&#x000a0;000 habitantes de todas las edades fueron de 3,6 (156/4&#x000a0;368&#x000a0;511) y de 1,1 (1&#x000a0;797/168&#x000a0;449&#x000a0;302) para los ind&#x000ed;genas y los no ind&#x000ed;genas respectivamente. El coeficiente de la tasa de los registros por edades fue de 4,0 (intervalo de confianza, IC, del 95%: 3,7&#x02013;4,3). Si se vacunara el 50% de los adultos ind&#x000ed;genas no inmunes (20% de todos los ind&#x000ed;genas adultos) en un programa de 10 a&#x000f1;os, se evitar&#x000ed;an de 527 a 549 nuevos casos de hepatitis B aguda.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>Sigue habiendo una gran desigualdad sanitaria entre los australianos ind&#x000ed;genas y los no ind&#x000ed;genas en relaci&#x000f3;n con la hepatitis B evitable con vacunas. Un programa de inmunizaci&#x000f3;n dirigido a adultos ind&#x000ed;genas australianos podr&#x000ed;a tener un impacto considerable para los casos de previsi&#x000f3;n de contagio de hepatitis B aguda, con un n&#x000fa;mero relativamente bajo de vacunas necesarias para evitar cada caso.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00642;&#x0064a;&#x00627;&#x00633; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00641;&#x00627;&#x00648;&#x0062a; &#x00641;&#x0064a; &#x0062d;&#x0062f;&#x00648;&#x0062b; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; <bold>&#x000a0; </bold>"B" &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00648;&#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x00623;&#x00633;&#x0062a;&#x00631;&#x00627;&#x00644;&#x0064a;&#x00627;&#x0060c; &#x00648;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062d;&#x0062a;&#x00645;&#x00644; &#x00644;&#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00636;&#x0062f; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; <bold>&#x000a0; </bold>"B" &#x00627;&#x00644;&#x00630;&#x0064a; &#x0064a;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x0063a;&#x0064a;&#x00631; &#x00645;&#x0062d;&#x00635;&#x00646;&#x0064a;&#x00646;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x0062d;&#x0062f;&#x00648;&#x0062b; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00648;&#x00646;&#x00633;&#x00628; &#x00627;&#x00644;&#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00642;&#x00648;&#x00645; &#x00628;&#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00648;&#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646;&#x0060c; &#x00645;&#x00639; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00627;&#x00644;&#x0062a;&#x00639;&#x0062f;&#x0064a;&#x00644;&#x00627;&#x0062a; &#x00644;&#x00645;&#x00639;&#x00627;&#x00644;&#x0062c;&#x00629; &#x00645;&#x00634;&#x00643;&#x00644;&#x00629; &#x00627;&#x00644;&#x00646;&#x00642;&#x00635; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00625;&#x00628;&#x00644;&#x00627;&#x0063a;&#x0060c; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00648;&#x00637;&#x00646;&#x0064a;&#x00629; &#x00639;&#x00646; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00645;&#x00624;&#x0062e;&#x00631;&#x0064b;&#x00627; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; "B" &#x00648;&#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0062a;&#x00645; &#x00627;&#x00644;&#x00625;&#x0062e;&#x00637;&#x00627;&#x00631; &#x00628;&#x00623;&#x00639;&#x0062f;&#x00627;&#x0062f;&#x00647;&#x00645; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x0064a; 2005 &#x00648; 2012. &#x00648;&#x0062a;&#x00645; &#x0062a;&#x00648;&#x00642;&#x00651;&#x00639; &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062d;&#x0062a;&#x00645;&#x00644; &#x00644;&#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00636;&#x0062f; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; "B" &#x00627;&#x00644;&#x00630;&#x0064a; &#x0064a;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x0063a;&#x0064a;&#x00631; &#x00645;&#x0062d;&#x00635;&#x00646;&#x0064a;&#x00646; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00627;&#x00643;&#x00627;&#x00629; &#x00644;&#x00633;&#x00644;&#x00633;&#x00644;&#x00629; &#x00645;&#x00627;&#x00631;&#x00643;&#x00648;&#x00641; &#x00645;&#x00648;&#x00646;&#x0062a; &#x00643;&#x00627;&#x00631;&#x00644;&#x00648;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00643;&#x00627;&#x00646; &#x00639;&#x0062f;&#x0062f; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062d;&#x0062f;&#x0064a;&#x0062b;&#x00629; &#x00628;&#x00627;&#x00644;&#x00645;&#x00631;&#x00636; &#x0064a;&#x00628;&#x00644;&#x0063a; 1953 &#x0062d;&#x00627;&#x00644;&#x00629; &#x00645;&#x00646; &#x00628;&#x0064a;&#x00646; 54,522 &#x00634;&#x0062e;&#x00635;&#x0064b;&#x00627; &#x00645;&#x00635;&#x00627;&#x00628;&#x0064b;&#x00627; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; "B" &#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645; &#x00627;&#x00644;&#x00625;&#x0062e;&#x00637;&#x00627;&#x00631; &#x00628;&#x00623;&#x00639;&#x0062f;&#x00627;&#x0062f;&#x00647;&#x00627; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00645;&#x00627; &#x00628;&#x0064a;&#x00646; 1 &#x0064a;&#x00646;&#x00627;&#x0064a;&#x00631;/&#x00643;&#x00627;&#x00646;&#x00648;&#x00646; &#x00627;&#x00644;&#x0062b;&#x00627;&#x00646;&#x0064a; 2005 &#x00648; 31 &#x0062f;&#x0064a;&#x00633;&#x00645;&#x00628;&#x00631;/&#x00643;&#x00627;&#x00646;&#x00648;&#x00646; &#x00627;&#x00644;&#x00623;&#x00648;&#x00644; 2012. &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x0062e;&#x00637;&#x00627;&#x00631; &#x00628;&#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; "B" &#x00627;&#x00644;&#x0062d;&#x00627;&#x0062f; &#x00623;&#x00639;&#x00644;&#x00649; &#x00628;&#x00643;&#x0062b;&#x0064a;&#x00631; &#x00644;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00633;&#x0062a;&#x00631;&#x00627;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00639;&#x00646; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646;. &#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x00648;&#x00641;&#x00642;&#x0064b;&#x00627; &#x00644;&#x00643;&#x00644; &#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00629; &#x0062a;&#x00636;&#x00645; 100,000 &#x00645;&#x00646; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00645;&#x00646; &#x0062c;&#x00645;&#x0064a;&#x00639; &#x00627;&#x00644;&#x00623;&#x00639;&#x00645;&#x00627;&#x00631; 3.6 (156/4,368,511&#x0200f;) &#x00648; 1.1 (1797/&#x0200f;168,449,302) &#x00644;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00648;&#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00627;&#x00644;&#x0064a;. &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x0062e;&#x00637;&#x00627;&#x00631; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00633;&#x00629; &#x00628;&#x00627;&#x00644;&#x00639;&#x00645;&#x00631; 4.0 (&#x00628;&#x00646;&#x00633;&#x00628;&#x00629; &#x00623;&#x00631;&#x0062c;&#x0062d;&#x0064a;&#x00629; &#x00645;&#x00642;&#x0062f;&#x00627;&#x00631;&#x00647;&#x00627; <styled-content style-type="direction" style="direction:ltr;">95&#x0200f;%</styled-content>: 3.7&#x02013;4.3). &#x00625;&#x00630;&#x00627; &#x0062a;&#x00645; &#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00646;&#x00633;&#x00628;&#x00629; &#x0062a;&#x00628;&#x00644;&#x0063a; <styled-content style-type="direction" style="direction:ltr;">50&#x0200f;% </styled-content>&#x00645;&#x00646; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00635;&#x00646;&#x0064a;&#x00646; <styled-content style-type="direction" style="direction:ltr;">(20&#x0200f;% </styled-content>&#x00645;&#x00646; &#x0062c;&#x00645;&#x0064a;&#x00639; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646;) &#x00645;&#x00646; &#x0062e;&#x00644;&#x00627;&#x00644; &#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x0064a;&#x00633;&#x0062a;&#x00645;&#x00631; &#x00644;&#x00645;&#x0062f;&#x00629; 10 &#x00623;&#x00639;&#x00648;&#x00627;&#x00645;&#x0060c; &#x00641;&#x00633;&#x0064a;&#x0062a;&#x00645; &#x0062a;&#x0062c;&#x00646;&#x00628; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00639;&#x0062f;&#x0062f; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00645;&#x0062a;&#x00648;&#x00642;&#x00639; &#x0064a;&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d; &#x00645;&#x00646; 527 &#x00625;&#x00644;&#x00649; 549 &#x0062d;&#x00627;&#x00644;&#x00629; &#x0062c;&#x0062f;&#x0064a;&#x0062f;&#x00629; &#x00645;&#x00646; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; "B". </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00644;&#x00627; &#x0064a;&#x00632;&#x00627;&#x00644; &#x00647;&#x00646;&#x00627;&#x00643; &#x00642;&#x0062f;&#x00631; &#x00643;&#x00628;&#x0064a;&#x00631; &#x00645;&#x00646; &#x00639;&#x0062f;&#x00645; &#x00627;&#x00644;&#x00645;&#x00633;&#x00627;&#x00648;&#x00627;&#x00629; &#x00641;&#x0064a; &#x00645;&#x0062c;&#x00627;&#x00644; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x0064a;&#x00629; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00633;&#x0062a;&#x00631;&#x00627;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00648;&#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00641;&#x0064a;&#x00645;&#x00627; &#x0064a;&#x0062a;&#x00639;&#x00644;&#x00642; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; "B" &#x00627;&#x00644;&#x00630;&#x0064a; &#x0064a;&#x00645;&#x00643;&#x00646; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00645;&#x00646;&#x00647; &#x00628;&#x0062a;&#x00648;&#x00641;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00644;&#x00642;&#x00627;&#x0062d;&#x00627;&#x0062a;. &#x00648;&#x0064a;&#x00645;&#x00643;&#x00646; &#x00623;&#x00646; &#x0064a;&#x00643;&#x00648;&#x00646; &#x00644;&#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00630;&#x0064a; &#x0064a;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641; &#x00627;&#x00644;&#x00623;&#x00633;&#x0062a;&#x00631;&#x00627;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00635;&#x00644;&#x0064a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646; &#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00643;&#x00628;&#x0064a;&#x00631; &#x00645;&#x00646; &#x0062d;&#x0064a;&#x0062b; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00646;&#x00645;&#x00637; "B" &#x00627;&#x00644;&#x0062d;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00645;&#x00646;&#x00647;&#x00627;&#x0060c; &#x00645;&#x00646; &#x0062e;&#x00644;&#x00627;&#x00644; &#x00648;&#x0062c;&#x00648;&#x0062f; &#x00623;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00642;&#x00644;&#x0064a;&#x00644;&#x00629; &#x00646;&#x00633;&#x00628;&#x0064a;&#x0064b;&#x00627; &#x00628;&#x0062d;&#x00627;&#x0062c;&#x00629; &#x00644;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00644;&#x00644;&#x00648;&#x00642;&#x00627;&#x0064a;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00645;&#x00631;&#x00636;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x091cf;&#x05316;&#x06fb3;&#x05927;&#x05229;&#x04e9a;&#x0571f;&#x08457;&#x0548c;&#x0975e;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x04e4b;&#x095f4;&#x07684;&#x04e59;&#x0809d;&#x053d1;&#x075c5;&#x07387;&#x05dee;&#x05f02;&#x0ff0c;&#x05e76;&#x04f30;&#x06d4b;&#x04ee5;&#x065e0;&#x0514d;&#x075ab;&#x0529b;&#x0571f;&#x08457;&#x06210;&#x05e74;&#x04eba;&#x04e3a;&#x076ee;&#x06807;&#x07fa4;&#x04f53;&#x07684;&#x04e59;&#x0809d;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x09879;&#x076ee;&#x07684;&#x06f5c;&#x05728;&#x05f71;&#x054cd;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06839;&#x0636e;&#x000a0;2005&#x000a0;&#x05e74;&#x081f3;&#x000a0;2012&#x000a0;&#x05e74;&#x095f4;&#x062a5;&#x0544a;&#x07684;&#x04e59;&#x0809d;&#x075c5;&#x06bd2;&#x0611f;&#x067d3;&#x04eba;&#x07fa4;&#x07684;&#x056fd;&#x05bb6;&#x06570;&#x0636e;&#x0ff0c;&#x0901a;&#x08fc7;&#x05bf9;&#x06bd4;&#x0571f;&#x08457;&#x0548c;&#x0975e;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x05e76;&#x09488;&#x05bf9;&#x06f0f;&#x062a5;&#x08fdb;&#x0884c;&#x076f8;&#x05e94;&#x08c03;&#x06574;&#x0ff0c;&#x06211;&#x04eec;&#x04f30;&#x06d4b;&#x04e86;&#x04e59;&#x0809d;&#x075c5;&#x06bd2;&#x0611f;&#x067d3;&#x07387;&#x053ca;&#x05176;&#x06bd4;&#x0503c;&#x03002; &#x091c7;&#x07528;&#x09a6c;&#x05c14;&#x079d1;&#x0592b;&#x08499;&#x07279;&#x05361;&#x07f57;&#x000a0;(Markov&#x000a0;chain&#x000a0;Monte&#x000a0;Carlo)&#x000a0;&#x06a21;&#x062df;&#x06a21;&#x0578b;&#x05448;&#x073b0;&#x04e86;&#x04ee5;&#x065e0;&#x0514d;&#x075ab;&#x0529b;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x04e3a;&#x076ee;&#x06807;&#x04eba;&#x07fa4;&#x07684;&#x04e59;&#x0809d;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x09879;&#x076ee;&#x07684;&#x06f5c;&#x05728;&#x05f71;&#x054cd;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>2005&#x000a0;&#x05e74;&#x000a0;1&#x000a0;&#x06708;&#x000a0;1&#x000a0;&#x065e5;&#x000a0;&#x081f3;&#x000a0;2012&#x000a0;&#x05e74;&#x000a0;12&#x000a0;&#x06708;&#x000a0;31&#x000a0;&#x065e5;&#x0671f;&#x095f4;&#x062a5;&#x0544a;&#x07684;&#x000a0;54&#x000a0;522&#x000a0;&#x04f8b;&#x04e59;&#x0809d;&#x075c5;&#x06bd2;&#x0643a;&#x05e26;&#x04eba;&#x07fa4;&#x04e2d;&#x0ff0c;1953&#x000a0;&#x04f8b;&#x04e3a;&#x065b0;&#x0611f;&#x067d3;&#x04eba;&#x07fa4;&#x03002; &#x06fb3;&#x05927;&#x05229;&#x04e9a;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x06025;&#x06027;&#x04e59;&#x0809d;&#x0611f;&#x067d3;&#x07684;&#x05448;&#x062a5;&#x07387;&#x08981;&#x08fdc;&#x08fdc;&#x09ad8;&#x051fa;&#x06fb3;&#x05927;&#x05229;&#x04e9a;&#x0975e;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x03002; &#x06bcf;&#x000a0;100&#x000a0;000&#x000a0;&#x04e07;&#x04eba;&#x053e3;&#x0ff08;&#x04e0d;&#x05206;&#x05e74;&#x09f84;&#x0ff09;&#x05f53;&#x04e2d;&#x0ff0c;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x0548c;&#x0975e;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x07684;&#x04e59;&#x0809d;&#x0611f;&#x067d3;&#x07387;&#x05206;&#x0522b;&#x0662f;&#x000a0;3.6&#x000a0;&#x0ff08;156/4&#x000a0;368&#x000a0;511&#x0ff09;&#x000a0;&#x0548c;&#x000a0;1.1&#x000a0;&#x0ff08;1797/168&#x000a0;449&#x000a0;302&#x0ff09;&#x03002; &#x05e74;&#x09f84;&#x06807;&#x051c6;&#x05316;&#x062a5;&#x0544a;&#x04e2d;&#x07684;&#x0611f;&#x067d3;&#x07387;&#x06bd4;&#x0503c;&#x04e3a;&#x000a0;4.0&#x000a0;&#x0ff08;95%&#x000a0;&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;&#x0ff1a;&#x000a0;3.7&#x02013;4.3)&#x03002; &#x05982;&#x0679c;&#x000a0;50%&#x000a0;&#x07684;&#x065e0;&#x0514d;&#x075ab;&#x0529b;&#x0571f;&#x08457;&#x06210;&#x05e74;&#x04eba;&#x0ff08;&#x05360;&#x06240;&#x06709;&#x0571f;&#x08457;&#x06210;&#x05e74;&#x04eba;&#x07684;&#x000a0;20%&#x0ff09;&#x05728;&#x000a0;10&#x000a0;&#x05e74;&#x0671f;&#x09879;&#x076ee;&#x04e2d;&#x063a5;&#x079cd;&#x04e59;&#x0809d;&#x075ab;&#x082d7;&#x0ff0c;&#x09884;&#x08ba1;&#x05c06;&#x04f1a;&#x06709;&#x000a0;527-549&#x000a0;&#x04eba;&#x0907f;&#x0514d;&#x0611f;&#x067d3;&#x06025;&#x06027;&#x04e59;&#x0809d;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x05728;&#x075ab;&#x082d7;&#x053ef;&#x09884;&#x09632;&#x04e59;&#x0578b;&#x0809d;&#x0708e;&#x075be;&#x075c5;&#x065b9;&#x09762;&#x0ff0c;&#x06fb3;&#x05927;&#x05229;&#x04e9a;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x04e0e;&#x0975e;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x04e4b;&#x095f4;&#x04ecd;&#x05c06;&#x05b58;&#x05728;&#x05de8;&#x05927;&#x07684;&#x05065;&#x05eb7;&#x04e0d;&#x05e73;&#x07b49;&#x06027;&#x03002; &#x05728;&#x09884;&#x09632;&#x06025;&#x06027;&#x04e59;&#x0578b;&#x0809d;&#x0708e;&#x065b9;&#x09762;&#x0ff0c;&#x04ee5;&#x06fb3;&#x05927;&#x05229;&#x04e9a;&#x0571f;&#x08457;&#x05c45;&#x06c11;&#x04e3a;&#x076ee;&#x06807;&#x07fa4;&#x04f53;&#x07684;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x09879;&#x076ee;&#x053ef;&#x080fd;&#x04f1a;&#x04ea7;&#x0751f;&#x076f8;&#x05f53;&#x05927;&#x07684;&#x05f71;&#x054cd;&#x0ff0c;&#x053ea;&#x06709;&#x076f8;&#x05bf9;&#x08f83;&#x05c11;&#x06570;&#x091cf;&#x07684;&#x05c45;&#x06c11;&#x09700;&#x08981;&#x063a5;&#x079cd;&#x075ab;&#x082d7;&#x04ee5;&#x09884;&#x09632;&#x06025;&#x06027;&#x04e59;&#x0578b;&#x0809d;&#x0708e;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x00421;&#x0043e;&#x0043f;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x00442;&#x0044c; &#x0043d;&#x00435;&#x00440;&#x00430;&#x00432;&#x0043d;&#x0043e;&#x0043c;&#x00435;&#x00440;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00430;&#x00432;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00439;&#x00446;&#x00435;&#x00432; &#x00438; &#x0043e;&#x00441;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00410;&#x00432;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00438; &#x00438; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x00442;&#x0044c; &#x0043f;&#x0043e;&#x00442;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x00432;&#x0043a;&#x0043b;&#x00430;&#x00434; &#x0043f;&#x00440;&#x00438;&#x00432;&#x00438;&#x00432;&#x0043e;&#x0043a; &#x0043e;&#x00442; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412; &#x00432; &#x00440;&#x00430;&#x0043c;&#x0043a;&#x00430;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x0043f;&#x0043e; &#x0043e;&#x00445;&#x00432;&#x00430;&#x00442;&#x00443; &#x0043d;&#x00435; &#x00438;&#x0043c;&#x00435;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00442;&#x00435;&#x00442;&#x00430; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00418;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x00443;&#x0044f; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043e; &#x0043b;&#x00438;&#x00446;&#x00430;&#x00445; &#x00441; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x0043c; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x0043e;&#x0043c;&#x000a0;&#x00412; &#x00437;&#x00430; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x00441; 2005 &#x0043f;&#x0043e; 2012&#x000a0;&#x00433;&#x0043e;&#x00434;, &#x0043c;&#x0044b; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x0043b;&#x00438; &#x00447;&#x00430;&#x00441;&#x00442;&#x0043e;&#x00442;&#x00443; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00437;&#x00430;&#x00440;&#x00430;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438; &#x00438;&#x00445; &#x00441;&#x0043e;&#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00448;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00438; &#x0043e;&#x00441;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441; &#x00443;&#x00447;&#x00435;&#x00442;&#x0043e;&#x0043c; &#x0043d;&#x00435;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x0043e;&#x00442;&#x0044b; &#x00441;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x00439;. &#x0041f;&#x0043e;&#x00442;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00435; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0043d;&#x00438;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412;, &#x0043e;&#x00445;&#x00432;&#x00430;&#x00442;&#x0044b;&#x00432;&#x00430;&#x0044e;&#x00449;&#x00435;&#x00439; &#x0043d;&#x00435; &#x00438;&#x0043c;&#x00435;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00442;&#x00435;&#x00442;&#x00430; &#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439; &#x00410;&#x00432;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00438;, &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00441;&#x0043f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043e; &#x0043f;&#x00440;&#x00438; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x00438; &#x00438;&#x0043c;&#x00438;&#x00442;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438; &#x0041c;&#x0043e;&#x0043d;&#x00442;&#x00435;-&#x0041a;&#x00430;&#x00440;&#x0043b;&#x0043e; &#x0043f;&#x0043e; &#x00441;&#x00445;&#x00435;&#x0043c;&#x00435; &#x0043c;&#x00430;&#x00440;&#x0043a;&#x0043e;&#x00432;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00446;&#x00435;&#x0043f;&#x00438;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00418;&#x00437; 54&#x000a0;522&#x000a0;&#x0043b;&#x00438;&#x00446; &#x00441; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x0043e;&#x0043c;&#x000a0;&#x00412;, &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; 1&#x000a0;&#x0044f;&#x0043d;&#x00432;&#x00430;&#x00440;&#x0044f; 2005&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430; &#x00438; 31&#x000a0;&#x00434;&#x00435;&#x0043a;&#x00430;&#x00431;&#x00440;&#x0044f; 2012&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430;, &#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00435; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00438; &#x00438;&#x0043d;&#x00444;&#x00438;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x0043e;&#x00442;&#x0043c;&#x00435;&#x00447;&#x00435;&#x0043d;&#x0044b; &#x00443; 1953&#x000a0;&#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;. &#x00421;&#x00442;&#x00435;&#x0043f;&#x00435;&#x0043d;&#x0044c; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043e;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00433;&#x0043e; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00410;&#x00432;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00438; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00432;&#x0044b;&#x00448;&#x00435;, &#x00447;&#x00435;&#x0043c; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043e;&#x00441;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x0044b;. &#x00412; &#x0043f;&#x00435;&#x00440;&#x00435;&#x00441;&#x00447;&#x00435;&#x00442;&#x00435; &#x0043d;&#x00430; 100&#x000a0;000&#x000a0;&#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00441;&#x00435;&#x00445; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x0043e;&#x00432; &#x0043e;&#x0043d;&#x00430; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00430; 3,6&#x000a0;(156&#x000a0;&#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x0043d;&#x00430; 4&#x000a0;368&#x000a0;511&#x000a0;&#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;) &#x00434;&#x0043b;&#x0044f; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00438; 1,1&#x000a0;(1797&#x000a0;&#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x0043d;&#x00430; 168&#x000a0;449&#x000a0;302&#x000a0;&#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;&#x00430;) &#x00434;&#x0043b;&#x0044f; &#x0043e;&#x00441;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x00421;&#x0043e;&#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00448;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00447;&#x00430;&#x00441;&#x00442;&#x0043e;&#x00442; &#x00443;&#x00432;&#x00435;&#x00434;&#x0043e;&#x0043c;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00439; &#x00441;&#x0043e; &#x00441;&#x00442;&#x00430;&#x0043d;&#x00434;&#x00430;&#x00440;&#x00442;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x0043f;&#x0043e; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x00443; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x0043e; 4,0&#x000a0;(95% &#x00434;&#x0043e;&#x00432;&#x00435;&#x00440;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x00438;&#x0043d;&#x00442;&#x00435;&#x00440;&#x00432;&#x00430;&#x0043b;: 3,7&#x02013;4,3). &#x00415;&#x00441;&#x0043b;&#x00438; &#x00431;&#x0044b; &#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x00442;&#x0044c; 50% &#x0043d;&#x00435; &#x00438;&#x0043c;&#x00435;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00442;&#x00435;&#x00442;&#x00430; &#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439;&#x000a0;(20% &#x00432;&#x00441;&#x00435;&#x00433;&#x0043e; &#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0043e;&#x00433;&#x0043e; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;), &#x00442;&#x0043e; &#x00437;&#x00430; 10&#x000a0;&#x0043b;&#x00435;&#x00442; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00431;&#x0044b; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00442;&#x00438;&#x00442;&#x0044c; 527&#x02013;549&#x000a0;&#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043e;&#x00441;&#x00442;&#x00440;&#x0044b;&#x0043c; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x0043e;&#x0043c;&#x000a0;&#x00412;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x0041f;&#x0043e;-&#x0043f;&#x00440;&#x00435;&#x00436;&#x0043d;&#x00435;&#x0043c;&#x00443; &#x00441;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x0044f;&#x00435;&#x00442;&#x00441;&#x0044f; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00435; &#x0043d;&#x00435;&#x00440;&#x00430;&#x00432;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x0043e; &#x00432; &#x0043e;&#x00431;&#x0043b;&#x00430;&#x00441;&#x00442;&#x00438; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x0043c; &#x00438; &#x0043e;&#x00441;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x0043c; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00410;&#x00432;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00438; &#x00432; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00449;&#x00430;&#x00435;&#x0043c;&#x0044b;&#x0043c; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x0043e;&#x0043c;&#x000a0;&#x00412;. &#x0041f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x00430; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438;, &#x0043d;&#x00430;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x00430;&#x0044f; &#x0043d;&#x00430; &#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0043e;&#x00435; &#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00435; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00410;&#x00432;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043b;&#x00438;&#x00438;, &#x0043c;&#x0043e;&#x00433;&#x0043b;&#x00430; &#x00431;&#x0044b; &#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x0044c; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00435; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00430; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00449;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x0043e;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00433;&#x0043e; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412;, &#x0043f;&#x00440;&#x00438; &#x0044d;&#x00442;&#x0043e;&#x0043c; &#x0043d;&#x00430; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00449;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043a;&#x00430;&#x00436;&#x00434;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x0044f; &#x00442;&#x00440;&#x00435;&#x00431;&#x00443;&#x00435;&#x00442;&#x00441;&#x0044f; &#x00443;&#x00434;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x00442;&#x0044c; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x0043d;&#x00435;&#x00431;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x0043e;&#x00435; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e; &#x0043b;&#x0044e;&#x00434;&#x00435;&#x00439;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Australia in 2016 has a population of approximately 24 million people. Indigenous Australians (Aboriginal and Torres Strait Islander peoples) constitute 3.0% of the population and have a younger age structure than non-indigenous Australians, similar to that of low- and middle-income countries.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> Although health indicators for the general Australian population are comparable with those of other high-income countries, life expectancy and the burden of many diseases is greater among indigenous Australians.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="R3" ref-type="bibr"><sup>3</sup></xref> The health disparities between indigenous and non-indigenous Australians have been acknowledged by the Australian government, which has implemented a whole-of-government strategy, entitled <italic>Closing the gap in indigenous disadvantage</italic>, aiming to completely remove these disparities by the year 2030.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref></p><p>Total viral hepatitis-related mortality in the Western Pacific Region of the World Health Organization (WHO) is now higher than deaths due to acquired immune deficiency syndrome, malaria and tuberculosis combined, constituting a critical public health challenge for the Region.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="R6" ref-type="bibr"><sup>6</sup></xref> In Australia, hepatitis B vaccination was recommended (but not nationally funded) for infants and adults in high-risk groups, including indigenous Australians, in the late 1980s.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> Universal vaccination of all infants commenced in the Northern Territory of Australia in 1990, followed by a funded national adolescent immunization programme starting in 1997. A funded universal infant hepatitis B immunization programme was introduced nationally in May 2000.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> The seroprevalence of hepatitis B virus surface antigen (HBsAg) in indigenous Australian adults was estimated to be 17% in a meta-analysis of studies conducted before 2000, thus meeting the WHO definition for high endemicity.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> Since then, HBsAg seroprevalence in indigenous Australians is estimated to have declined to 3.7% of the 548&#x02009;366 population nationally in 2011.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> This is a WHO-defined intermediate level of endemicity, but is still more than 10 times the rate in non-indigenous Australians born in Australia (0.3% of 13&#x02009;836&#x02009;559, excluding people who inject drugs and men who have sex with men).<xref rid="R9" ref-type="bibr"><sup>9</sup></xref></p><p>Indigenous Australians also have a higher prevalence of comorbidities such as type 2 diabetes mellitus and alcohol-related liver disease<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> which are associated with poorer prognosis and more rapid progression of chronic hepatitis B.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> The incidence of liver cancer is up to 10 times higher compared with non-indigenous Australians.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R9" ref-type="bibr"><sup>9</sup></xref> In the light of this increased risk, indigenous Australians have been identified as a priority group for hepatitis B testing and immunization.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref><sup>&#x02013;</sup><xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Universal hepatitis B infant immunization is funded under the Australian national immunization programme, with a school-based adolescent catch-up programme funded to 2013 (by which time the cohort immunized in infancy will have reached adolescence). However, funding and access to hepatitis B vaccination for adults at higher risk, including indigenous Australians, is limited and inconsistent across the eight Australian states and territories (jurisdictions).<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> Although data on hepatitis B vaccination coverage in indigenous adults are very limited, we believe that national coverage is likely to be low. This view is based on various evidence: from a sentinel study quantifying vaccination coverage from analysis of markers of hepatitis B infection;<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> from the poor coverage achieved in funded influenza and pneumococcal vaccination programmes targeted on indigenous adults aged 18&#x02013;49 years with relevant risk factors;<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> and on the basis of the ongoing higher rate of incident infections in indigenous than non-indigenous adults.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref></p><p>In this study, we aimed to review the epidemiology of newly acquired hepatitis B (the vaccine-preventable fraction of the burden of disease) in indigenous and non-indigenous people in Australia. We also estimated the potential impact of more systematic implementation of hepatitis B vaccination for all non-immune indigenous Australian adults.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Data sources</title><p>Data on all cases of hepatitis B notified from 1 January 2005 to 31 December 2012 were obtained from the Australian National Notifiable Diseases Surveillance System (NNDSS).<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> The NNDSS compiles notification data from all eight Australian jurisdictions. Variables extracted for analysis included year of notification, age, sex, jurisdiction and indigenous status.</p><p>Data on the mid-year estimated national resident population for the same years (2005&#x02013;2012) by jurisdiction; indigenous status and age were obtained from the Australian Bureau of Statistics.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref></p><sec><title>Definitions</title><p>Indigenous notifications included all individuals with hepatitis B notification whose indigenous status was recorded in the NNDSS as Aboriginal or Torres Strait Islander, or both; non-indigenous notifications included all other individuals with hepatitis B notification, including those whose indigenous status was unknown. The indigenous population was individuals who self-identified in the Australian census as being Aboriginal or Torres Strait Islander, or both (with the numbers adjusted for net undercount measured by a post-enumeration survey); non-indigenous was the remaining resident Australian population.</p><p>Since 2004 the national surveillance case definition of newly acquired (i.e. acute) hepatitis B is based on laboratory confirmation of infection by one of the following criteria: (i)&#x000a0;detection of HBsAg in a patient shown to be negative within the last 24 months; or (ii)&#x000a0;detection of HBsAg and of immunoglobulin (Ig) M to hepatitis B core antigen (anti-HBc IgM), in the absence of prior evidence of hepatitis B virus infection; or (iii)&#x000a0;detection of hepatitis B virus by nucleic acid testing and of anti-HBc IgM, in the absence of prior evidence of hepatitis B virus infection.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> Confirmed cases of newly acquired hepatitis B are notifiable under public health legislation in each jurisdiction. Unspecified cases of hepatitis B (those with laboratory-definitive evidence but not meeting any of the criteria for a newly acquired case)<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> are assumed to be predominantly episodes of chronic hepatitis B and are notifiable.</p></sec><sec><title>Ethical considerations</title><p>Ethics approval was not required for this study as de-identified, aggregate population-based data were used for routine public health purposes only.</p></sec></sec><sec><title>Data analysis</title><p>Analysis was restricted to newly acquired hepatitis B notification data. This was because the unspecified hepatitis&#x000a0;B notification data do not differentiate between acute and chronic hepatitis&#x000a0;B. Data were analysed by age group, sex, jurisdiction and indigenous status. While the completeness of recording indigenous status in notification data has improved, some variation exists between jurisdictions and over time. For this analysis, individuals whose indigenous status was unknown were classified as non-indigenous, according to established practice.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> To assess any impact of under-identification of indigenous status, a separate analysis was undertaken excluding data from jurisdictions that had completeness of recording indigenous status below 95%.</p><p>Australian Bureau of Statistics&#x02019; population data were used to calculate hepatitis B notification rates per 100&#x02009;000 population and perform direct age standardization using the total Australian resident population as the standard.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> Rate ratios comparing notification rates for indigenous and other Australians were calculated with 95% confidence intervals (CI). Analyses were performed using Stata statistical software version 12.0 (Stata Corp., College Station, United States of America [USA]).</p><sec><title>Vaccination impact estimates</title><p>The proportion of indigenous Australians aged 15 years or older who were non-immune, by age group, was estimated from Australian Bureau of Statistics&#x02019; population data<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> and the authors&#x02019; (FB) expert opinion (<xref ref-type="table" rid="T1">Table&#x000a0;1</xref>). Expert opinion was based on a review of published HBsAg seroprevalence data<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>&#x02013;</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref> and published<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> and unpublished hepatitis B vaccination coverage estimates, and was informed by previous experience implementing immunization programmes targeting indigenous Australians. While hepatitis B vaccination coverage in indigenous Australian infants has been consistently high (in the vicinity of 95%) after universal immunization was introduced in the year 2000,<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref> coverage for adolescents was estimated to have been moderate and for adults was estimated to have been poor. We also accounted for the complexity involved in delivery of a hepatitis B immunization programme (including baseline serological testing and administration of three doses of vaccine).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Values and probability distribution of model parameters for estimating the impact of a hepatitis B immunization programme for non-immune indigenous people aged &#x02265;&#x02009;15 years in Australia</title></caption><table frame="hsides" rules="groups"><col width="38" span="1"/><col width="66" span="1"/><col width="66" span="1"/><col width="70" span="1"/><col width="59" span="1"/><col width="92" span="1"/><col width="109" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Age group, years</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Estimated indigenous population, no.<sup>a</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Estimated % susceptible (range)<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Estimated susceptible, no.</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Estimated baseline no. of new infections per year<sup>c</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Seroconversion rate from vaccination (range)<sup>d</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Estimated risk of progression to chronic infection in newly acquired cases (range)<sup>e</sup></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">15&#x02013;19</td><td valign="top" align="center" rowspan="1" colspan="1">72&#x02009;782</td><td valign="top" align="center" rowspan="1" colspan="1">30 (20&#x02013;40)</td><td valign="top" align="center" rowspan="1" colspan="1">21&#x02009;835</td><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">0.95 (0.93&#x02013;0.97)</td><td valign="top" align="center" rowspan="1" colspan="1">0.10 (0.08&#x02013;0.15)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">20&#x02013;24</td><td valign="top" align="center" rowspan="1" colspan="1">61&#x02009;166</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">24&#x02009;466</td><td valign="top" align="center" rowspan="1" colspan="1">44</td><td valign="top" align="center" rowspan="1" colspan="1">0.90 (0.85&#x02013;0.95)</td><td valign="top" align="center" rowspan="1" colspan="1">0.08 (0.07&#x02013;0.11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">25&#x02013;29</td><td valign="top" align="center" rowspan="1" colspan="1">50&#x02009;390</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;156</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">0.90 (0.85&#x02013;0.95)</td><td valign="top" align="center" rowspan="1" colspan="1">0.08 (0.07&#x02013;0.11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">30&#x02013;34</td><td valign="top" align="center" rowspan="1" colspan="1">40&#x02009;681</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">16&#x02009;272</td><td valign="top" align="center" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">0.90 (0.85&#x02013;0.95)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">35&#x02013;39</td><td valign="top" align="center" rowspan="1" colspan="1">41&#x02009;300</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">16&#x02009;520</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">0.90 (0.85&#x02013;0.95)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">40&#x02013;44</td><td valign="top" align="center" rowspan="1" colspan="1">40&#x02009;507</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">16&#x02009;203</td><td valign="top" align="center" rowspan="1" colspan="1">18</td><td valign="top" align="center" rowspan="1" colspan="1">0.75 (0.70&#x02013;0.80)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">45&#x02013;49</td><td valign="top" align="center" rowspan="1" colspan="1">34&#x02009;189</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">13&#x02009;676</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">0.75 (0.70&#x02013;0.80)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">50&#x02013;54</td><td valign="top" align="center" rowspan="1" colspan="1">28&#x02009;812</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;525</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.65 (0.60&#x02013;0.70)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">55&#x02013;59</td><td valign="top" align="center" rowspan="1" colspan="1">21&#x02009;562</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x02009;625</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.65 (0.60&#x02013;0.70)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">60&#x02013;64</td><td valign="top" align="center" rowspan="1" colspan="1">15&#x02009;190</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x02009;076</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.65 (0.60&#x02013;0.70)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">65&#x02013;69</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x02009;680</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02009;872</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (0.35&#x02013;0.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">70&#x02013;74</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x02009;972</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x02009;389</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (0.35&#x02013;0.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02265;&#x02009;75</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x02009;030</td><td valign="top" align="center" rowspan="1" colspan="1">40 (30&#x02013;50)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x02009;812</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (0.35&#x02013;0.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.01&#x02013;0.10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Total</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>429&#x02009;261</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>NA</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>164&#x02009;427</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>193</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>NA</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>NA</bold></td></tr></tbody></table><table-wrap-foot><p>NA:&#x02009;not applicable.</p><p><sup>a</sup> Estimated population from Australian Bureau of Statistics data.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref></p><p><sup>b</sup> On the basis of author&#x02019;s (FB) expert opinion informed by review of published data on seroprevalence of hepatitis B virus surface antigen<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>&#x02013;</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref> and published data<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> and unpublished estimates on hepatitis B vaccination coverage. While hepatitis B vaccination coverage in indigenous Australian infants has been consistently high (in the vicinity of 95%) after universal immunization was introduced in the year 2000,<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref> coverage for adolescents was estimated to have been moderate and for adults was estimated to have been poor.</p><p><sup>c</sup> Average annual number of notifications to the Australian national notifiable diseases surveillance system over the years 2005&#x02013;2012, multiplied by 10.<xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref></p><p><sup>d</sup> Point estimates were derived from the literature for areas with intermediate or low endemicity for adolescents<xref rid="R33" ref-type="bibr"><sup>33</sup></xref><sup>&#x02013;</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref> and adults.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref><sup>&#x02013;</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref> The values of lower and upper limits were based on the author&#x02019;s (FB) expert opinion.</p><p><sup>e</sup> Estimate from Edmunds et al. 1993.<xref rid="R45" ref-type="bibr"><sup>45</sup></xref></p><p>Notes: Risk of developing acute infection in susceptible individuals was calculated by dividing no. of newly acquired cases by age-specific population counts. Projected cumulative additional immunization coverage is presented in <xref ref-type="table" rid="T2">Table&#x000a0;2</xref>.</p></table-wrap-foot></table-wrap><p>On this basis we estimated the potential impact of hepatitis B immunization for two vaccination coverage scenarios: (i)&#x000a0;low coverage, in which 25% of the susceptible population of 164&#x02009;427 were vaccinated by the end of the 10-year programme, and (ii)&#x000a0;high coverage, in which 50% of the susceptible population was vaccinated. These figures correspond to 10% and 20% respectively of the total indigenous adult population. A range of possible coverage, determined by author&#x02019;s (FB) expert opinion, was used for each of these scenarios, with cumulative coverage plotted for each year of the 10-year programme (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref>; available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/bulletin/volumes/94/11/16-169524">http://www.who.int/bulletin/volumes/94/11/16-169524</ext-link>). We also used the model to estimate the vaccination coverage level at which hepatitis B incidence among indigenous Australians would be reduced to the current rate among non-indigenous Australians.</p><table-wrap id="T2" specific-use="online" orientation="portrait" position="float"><label>Table 2</label><caption><title>Projected cumulative additional hepatitis B immunization coverage of susceptible indigenous people aged &#x02265;&#x02009;15 years in Australia, over a 10-year immunization programme, for two vaccination coverage scenarios</title></caption><table frame="hsides" rules="groups"><col width="53" span="1"/><col width="90" span="1"/><col width="93" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Year</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Projected % (range) of population vaccinated<sup>a</sup><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Low coverage scenario<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">High coverage scenario<sup>b</sup></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">5 (2&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (15&#x02013;25)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">8 (5&#x02013;11)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (19&#x02013;29)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">11 (8&#x02013;14)</td><td valign="top" align="center" rowspan="1" colspan="1">28 (23&#x02013;33)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">13 (10&#x02013;16)</td><td valign="top" align="center" rowspan="1" colspan="1">32 (27&#x02013;37)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">15 (12&#x02013;18)</td><td valign="top" align="center" rowspan="1" colspan="1">35 (30&#x02013;40)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">18 (15&#x02013;21)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (33&#x02013;43)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">21 (18&#x02013;24)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (36&#x02013;46)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">25 (21&#x02013;28)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (39&#x02013;49)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">9</td><td valign="top" align="center" rowspan="1" colspan="1">25 (21&#x02013;28)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (42&#x02013;52)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">25 (21&#x02013;28)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (45&#x02013;55)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> For a completed course of three doses of vaccine; coverage was assumed to be the same across age groups (&#x02265;&#x02009;15 years); range applicable to Markov chain Monte Carlo model.</p><p><sup>b</sup> Low coverage scenario assumed 25% of the total susceptible indigenous adult population vaccinated after 10 years. High coverage scenario assumed 50% vaccinated.</p><p>Note: The estimated population size of susceptible indigenous Australians aged &#x02265;&#x02009;15 years was 164&#x02009;427.</p></table-wrap-foot></table-wrap><p>We estimated the impact of a hepatitis B immunization programme for non-immune indigenous Australians aged &#x02265;&#x02009;15 years in terms of the number of cases of acute and additional chronic hepatitis B infections prevented, and the number needed to vaccinate to prevent each case. To do this we developed a Markov chain Monte Carlo simulation using a random walk (i.e. a computerized run-through of&#x02009;100&#x02009;000 scenarios, each with variables randomly selected from the range of parameter values outlined in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>), using Excel 2010 software (Microsoft Corp., Redmond, USA). Our model was built on a Markov chain with one-year cycles and allowed for age-dependent transitions. This type of model structure conceptualizes health or disease status as a series of mutually exclusive and collectively exhaustive health states. In each cycle of the model, individuals either reside in one of the health states, or transition probabilistically to another at the end of a given cycle. Health benefits are accrued based on the state occupied during a given cycle. </p><p>A decision tree was used to compare the impact of a hepatitis B immunization programme targeting indigenous Australian adults, in terms of progression to acute or chronic infection, against the baseline of current practice (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Decision tree used for estimating potential impact of hepatitis B immunization programme among indigenous people in Australia</p></caption><graphic xlink:href="BLT.16.169524-F1"/></fig><p>The variables incorporated into the model included: age group, estimated population, estimated proportion of people susceptible to hepatitis B, estimated baseline number of acute infections per year and vaccination seroconversion rate. Estimates of the risk of susceptible individuals developing acute infection and of progression to chronic infection were also incorporated into the model; these were derived from the literature from areas with intermediate or low endemicity for adolescents<xref rid="R33" ref-type="bibr"><sup>33</sup></xref><sup>&#x02013;</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref> and adults.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref></p><p>For the probability distribution of age group-specific parameters (<xref ref-type="table" rid="T1">Table&#x000a0;1</xref>), we assumed a normal distribution for the proportion of the population susceptible to hepatitis B infection, the seroconversion rate after vaccination and the projected cumulative additional vaccination coverage achieved in the hypothetical 10-year immunization programme. We used a triangular distribution for the risk of progression to chronic infection in newly acquired cases.</p><p>The key assumptions used in our model were as follows. Records of newly acquired cases in the NNDSS were considered as cases of acute hepatitis B virus infection. To adjust for underreporting and misclassification of acute hepatitis B infection, we used previously modelled data from Australia (similar to estimates from the USA)<xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R46" ref-type="bibr"><sup>46</sup></xref> to estimate the true number of acute infections. We did this by applying a multiplier of 10 to the average annual number of NNDSS notifications of newly acquired hepatitis&#x000a0;B for each age group over the period 2005&#x02013;2012. Vaccine efficacy was considered all-or-nothing rather than leaky (partial protection). Vaccine efficacy for specific age groups was assumed to be equivalent to the seroconversion rate derived from overseas studies, as this is a well-established and robust surrogate of clinical protection.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> Infected individuals or seroconverted vaccinees were assumed to stay immune indefinitely. Finally, individuals younger than 15 years at the programme start, but who subsequently entered the model when they reached 15 years of age during the modelled programme, were assumed to be immune due to high levels of vaccination coverage in this cohort.</p><p>The potential effects on herd protection and mother-to-child transmission were not factored into the model. Any additional vaccination coverage achieved over the 10-year period through existing mechanisms (characterized by inconsistent funding and poor promotion) was assumed to be low and was not factored into the model.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Notifications</title><p>There were 54&#x02009;522 notifications of hepatitis B disease between 1 January 2005 and 31 December 2012, 52&#x02009;569 (96%) of which were recorded as unspecified and 1953 (4%) as newly acquired. Of the newly acquired infections, 156 (8%) were recorded as being in indigenous persons. The overall notification rate over eight years in indigenous persons was 3.6 per 100&#x02009;000 population (156/4&#x02009;368&#x02009;511) compared with 1.1 per 100&#x02009;000 (1797/168&#x02009;449&#x02009;302) in the non-indigenous population. The age-standardized rate ratio for newly acquired hepatitis B for all ages from all jurisdictions over the study period was 4.0 (95% CI: 3.7&#x02013;4.3) for indigenous Australians (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). For the three jurisdictions with the highest (&#x02265;&#x02009;95%) completeness of recording indigenous status (Western Australia, South Australia and the Northern Territory), the age-standardized rate ratio was 4.7 (95% CI: 4.0&#x02013;5.5). The notification rate ratio for indigenous Australians compared with other Australians over the study period were significantly higher in all age groups &#x02265;&#x02009;15 years, ranging from 3.4 (95% CI: 2.4&#x02013;4.6) in the 30&#x02013;39 years age group to 7.3 (95% CI: 4.1&#x02013;12.5) in the 15&#x02013;19 years age group (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Notification rates for newly acquired hepatitis B virus infections (total 1953) and rate ratios, by age group and indigenous status, Australia, 2005&#x02013;2012</title></caption><table frame="hsides" rules="groups"><col width="113" span="1"/><col width="83" span="1"/><col width="82" span="1"/><col width="85" span="1"/><col width="90" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Age group, by indigenous status<sup>a</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Population, no.</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of notifications</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Notification rate per 100&#x02009;000 population<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Rate ratio (95% CI)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>0&#x02013;14 years</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;576&#x02009;636</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td><td rowspan="2" valign="top" align="center" colspan="1">2.6 (0.7&#x02013;7.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">31&#x02009;579&#x02009;216</td><td valign="top" align="center" rowspan="1" colspan="1">30</td><td valign="top" align="center" rowspan="1" colspan="1">0.1</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>15&#x02013;19 years</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">481&#x02009;829</td><td valign="top" align="center" rowspan="1" colspan="1">18</td><td valign="top" align="center" rowspan="1" colspan="1">4.2</td><td rowspan="2" valign="top" align="center" colspan="1">7.3 (4.1&#x02013;12.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;273&#x02009;295</td><td valign="top" align="center" rowspan="1" colspan="1">61</td><td valign="top" align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>20&#x02013;29 years</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">719&#x02009;869</td><td valign="top" align="center" rowspan="1" colspan="1">58</td><td valign="top" align="center" rowspan="1" colspan="1">9.1</td><td rowspan="2" valign="top" align="center" colspan="1">3.9 (2.9&#x02013;5.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">24&#x02009;204&#x02009;768</td><td valign="top" align="center" rowspan="1" colspan="1">514</td><td valign="top" align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>30&#x02013;39 years</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">572&#x02009;789</td><td valign="top" align="center" rowspan="1" colspan="1">43</td><td valign="top" align="center" rowspan="1" colspan="1">7.8</td><td rowspan="2" valign="top" align="center" colspan="1">3.4 (2.4&#x02013;4.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">24&#x02009;137&#x02009;421</td><td valign="top" align="center" rowspan="1" colspan="1">529</td><td valign="top" align="center" rowspan="1" colspan="1">2.3</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold> &#x02265;&#x02009;40 years</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;017&#x02009;388</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">3.5</td><td rowspan="2" valign="top" align="center" colspan="1">4.3 (3.0&#x02013;6.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">77&#x02009;254&#x02009;602</td><td valign="top" align="center" rowspan="1" colspan="1">663</td><td valign="top" align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>All ages (age-standardized)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">4.3</td><td rowspan="2" valign="top" align="center" colspan="1">4.0 (3.7&#x02013;4.3)<sup>c</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-indigenous</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">1.1</td></tr></tbody></table><table-wrap-foot><p>CI: confidence interval; NA: not applicable.</p><p><sup>a</sup> Indigenous population was individuals who self-identified in the Australian census as being Aboriginal or Torres Strait Islander or both (with the numbers adjusted for net undercount measured by a post-enumeration survey); non-indigenous was the remaining resident Australian population. Indigenous notifications included all individuals with hepatitis B notification whose indigenous status was recorded in the Australian national notifiable diseases surveillance system as Aboriginal or Torres Strait Islander or both; non-indigenous notifications included all other individuals with hepatitis B notification, including those whose indigenous status was unknown. </p><p><sup>b</sup> Age-specific average annual rate of notifications.</p><p><sup>c</sup> Rate ratio for all ages calculated using direct age standardization with all Australians as the standard.</p></table-wrap-foot></table-wrap><p>Notification rates for newly acquired hepatitis B between 2005 and 2012 showed no significant changes over time for indigenous Australians (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>). However, there was a significant downward trend in the annual notification rate for non-indigenous Australians, falling from 1.1 per 100&#x02009;000 population in 2005 to 0.8 per 100&#x02009;000 in 2012 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). The annual rate ratios for newly acquired hepatitis B showed no significant change over the period (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>).</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Trends in notification rates of newly acquired hepatitis B (left axis) and corresponding age-standardized rate ratios (right axis) by indigenous status, Australia, 2005&#x02013;2012</p></caption><p>Note: Rate ratios were calculated using direct age standardization with the total Australian resident population as the standard.</p><graphic xlink:href="BLT.16.169524-F2"/></fig></sec><sec><title>Vaccination impact estimates</title><p>We estimated the size of the hepatitis&#x000a0;B non-immune indigenous Australian population aged &#x02265;&#x02009;15 years to be approximately 164&#x02009;000 (38% of the total indigenous population aged &#x02265;&#x02009;15 years of 429&#x02009;261; <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>). </p><p>With no additional adult vaccination coverage above that already occurring, modelling predicted an additional 1792 new acute hepatitis B cases in indigenous individuals aged &#x02265;&#x02009;15 years over a 10-year period.</p><p>Potential health gains for each scenario are summarized in <xref ref-type="table" rid="T4">Table&#x000a0;4</xref>; the projected annual trends in acute hepatitis B incidence over a 10-year immunization programme are shown in <xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>. In the first scenario, whereby 25% (range: 21&#x02013;28%) of susceptible indigenous adults are vaccinated, the model predicted between 240 and 251 new cases of acute hepatitis B would be prevented across 10&#x000a0;years. The corresponding number of persons needed to vaccinate to prevent one case of acute hepatitis B under this scenario would be between 149 and 181 (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>). In the second scenario whereby 50% (range: 45&#x02013;55%) of susceptible indigenous adults are vaccinated over a 10-year period, between 527 and 549 new cases of acute hepatitis B were predicted to be prevented, with an estimated number needed to vaccinate of between 138 and 163 (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Projected impact on number of acute and chronic cases of hepatitis B in a 10-year immunization programme for indigenous people aged &#x02265;&#x02009;15 years in Australia, by vaccination coverage</title></caption><table frame="hsides" rules="groups"><col width="100" span="1"/><col width="96" span="1"/><col width="98" span="1"/><col width="92" span="1"/><col width="113" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Vaccination coverage</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Acute hepatitis B<sup>a</sup><hr/></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Chronic hepatitis B<sup>b</sup><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">No. of cases prevented (95% UI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of people needed to vaccinate (UI)<sup>c</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of cases prevented (95% UI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of people needed to vaccinate (UI)<sup>c</sup></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Low coverage scenario<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">246 (240&#x02013;251)</td><td valign="top" align="center" rowspan="1" colspan="1">164 (149&#x02013;181)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (22&#x02013;24)</td><td valign="top" align="center" rowspan="1" colspan="1">1776 (1565&#x02013;2009)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">High coverage scenario<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">538 (527&#x02013;549)</td><td valign="top" align="center" rowspan="1" colspan="1">150 (138&#x02013;163)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (48&#x02013;52)</td><td valign="top" align="center" rowspan="1" colspan="1">1620 (1460&#x02013;1793)</td></tr></tbody></table><table-wrap-foot><p>UI: uncertainty interval.</p><p><sup>a</sup> Newly acquired infection.</p><p><sup>b</sup> Persistent infection (hepatitis B surface antigen positive for &#x02265;&#x02009;6&#x000a0;months post-infection).</p><p><sup>c</sup> Estimates of lower and upper limits for Markov chain Monte Carlo model. Number needed to vaccinate were calculated using bounds of 95% confidence interval (CI) of modelled number of cases prevented and bounds of 95% CIs of modelled number of vaccinees.</p><p><sup>d</sup> Projected coverage across a 10-year immunization programme. Low coverage scenario assumed 25% of the total susceptible indigenous adult population vaccinated after 10 years. High coverage scenario assumed 50% vaccinated.</p><p>Note: The estimated population size of susceptible indigenous Australians aged &#x02265;&#x02009;15 years was 164&#x02009;427.</p></table-wrap-foot></table-wrap><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Projected annual trends in acute hepatitis B incidence over a 10-year immunization programme among indigenous people aged &#x02265;&#x02009;15 years in Australia, by vaccination coverage scenario</p></caption><p>Note: Vaccination coverage scenario in susceptible individuals was for completed course of three doses of vaccine and excluding impact of herd immunity. Low coverage scenario assumed 25% of the total susceptible indigenous adult population vaccinated after 10 years. High coverage scenario assumed 50% vaccinated.</p><graphic xlink:href="BLT.16.169524-F3"/></fig><p>For chronic hepatitis B the projected numbers of cases prevented were proportionately lower and the number needed to vaccinate were higher for both scenarios (<xref ref-type="table" rid="T4">Table&#x000a0;4</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Consistent with a previous study,<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> we found that rates of notification for newly acquired hepatitis B were significantly higher for indigenous than non-indigenous Australians. Low rates of acute hepatitis B infection in both indigenous and non-indigenous Australians younger than 15&#x000a0;years<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> reflect the success of the universal infant hepatitis&#x000a0;B immunization programme, which began in Australia in 2000, building on targeted programmes during the preceding decade.</p><p>While current Australian guidelines recommend hepatitis B vaccination to be offered to all non-immune indigenous Australians, vaccination for indigenous adults is not funded under the national immunization programme and current uptake is thought to be poor. Our study shows that a hepatitis B immunization programme for indigenous Australians aged &#x02265;&#x02009;15&#x000a0;years could have considerable impact in terms of cases of acute hepatitis B prevented, with a relatively low number of persons needed to vaccinate to prevent each case. Prevention of acute hepatitis B infection would also have an impact on the ultimate number of cases of chronic infection. Without such a programme, it will almost certainly take several decades for the disparity in rates of acute hepatitis B infection between indigenous and non-indigenous Australian adults to reduce, as those vaccinated as infants gradually age into adulthood.</p><p>As of 2008, 177 countries had introduced hepatitis B vaccine into their national infant immunization programmes.<xref rid="R47" ref-type="bibr"><sup>47</sup></xref> This is estimated to have prevented more than 80% of the 1&#x02009;400&#x02009;000 hepatitis-B-related deaths that would otherwise have occurred worldwide since WHO&#x02019;s initial recommendation in 1997.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> Our findings support WHO&#x02019;s recommendation that catch-up campaigns for hepatitis B vaccination be considered for adolescents or adults in high-prevalence settings once infant immunization is established.<xref rid="R47" ref-type="bibr"><sup>47</sup></xref> Modelling similar to that conducted in our study could be used to estimate the impact of catch-up programmes in such settings or in high-risk populations in intermediate- or low-prevalence settings. The benefits of catch-up hepatitis B strategies for higher-risk populations in countries with intermediate or low endemicity are also reflected in the WHO guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection;<xref rid="R49" ref-type="bibr"><sup>49</sup></xref> so too is a particular focus on offering screening, vaccination and treatment for hepatitis B to indigenous peoples. For example, a catch-up hepatitis B immunization programme for adolescents aged 15&#x02013;19 years was estimated to be cost saving in China<xref rid="R50" ref-type="bibr"><sup>50</sup></xref> and was subsequently implemented with good effect.<xref rid="R51" ref-type="bibr"><sup>51</sup></xref> Another campaign targeting young adults aged 21&#x02013;39 years in China has also been estimated to be cost saving.<xref rid="R51" ref-type="bibr"><sup>51</sup></xref></p><p>Our study had several limitations. We did not use a dynamic model, primarily due to the lack of data on contact mixing patterns applicable to the indigenous population in Australia. The static Markov chain Monte Carlo method we used is not able to capture herd protection effects, which could be substantial considering the well-documented household overcrowding and heightened disease transmission that occurs within indigenous communities.<xref rid="R52" ref-type="bibr"><sup>52</sup></xref> Also, we did not evaluate any potential incremental benefits on prevention of mother-to-child transmission. This route of transmission is uncommon in Australia, including in indigenous populations, due to the high quality of antenatal care and neonatal immunization. Nor did we estimate the protection afforded to additional individuals who may receive an incomplete course of vaccinations. Grouping notifications from people with unknown indigenous status with non-indigenous status likely underestimates the true disparity between indigenous and non-indigenous populations.<xref rid="R53" ref-type="bibr"><sup>53</sup></xref> Lower access to health care may also contribute to underestimation of notification rates for indigenous Australians. However, this may be counteracted by recommendations in national guidelines to test all indigenous Australians for hepatitis B virus infection. We did not factor in any impact of vaccination coverage achieved through existing mechanisms over the 10-year period as this was assumed to be low. On balance, these limitations are likely to result in our estimates of potential impact being conservative.</p><p>Our study findings highlight the health disparity in hepatitis B infection between indigenous and non-indigenous Australians. This is connected to the overall disadvantage faced by indigenous Australians, which is due to a complex combination of inter-related socioeconomic, cultural and historical determinants.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> It is also likely that hepatitis B was highly prevalent in the indigenous population before infant immunization programmes began. Multiple initiatives at many levels by the Australian government have been put in place to address the broader issues of indigenous disadvantage. The findings of our study suggest that this disparity in hepatitis B could be readily and rapidly eliminated through a modest increase in vaccination coverage among indigenous Australian adults, for example through a funded vaccination catch-up programme.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank E Jacyna, C King, A Dey and H Wang. </p></ack><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>The National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases is supported by the Australian Government Department of Health, the New South Wales Ministry of Health and the Children&#x02019;s Hospital at Westmead. </p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="web">Estimates of Aboriginal and Torres Strait Islander Australians [3238.0.55.001]. Canberra: Australian Bureau of Statistics; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3238.0.55.001Main+Features1June%202011?OpenDocument">http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3238.0.55.001Main+Features1June%202011?OpenDocument</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2013 Nov 5].</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="book"><string-name><surname>Vos</surname>
<given-names>TBB</given-names></string-name>, <string-name><surname>Stanley</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>AD</given-names></string-name>. <article-title>The burden of disease and injury in Aboriginal and Torres Strait Islander peoples 2003</article-title>. <publisher-loc>Brisbane</publisher-loc>: <collab>School of Population Health, University of Queensland</collab>; <year>2007</year>.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="web">Life expectancy of Aboriginal and Torres Strait Islander people. Canberra: Australian Institute of Health and Welfare; 2011. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.aihw.gov.au/deaths/life-expectancy/#indigenous">http://www.aihw.gov.au/deaths/life-expectancy/#indigenous</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2016 June 27].</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="web">Closing the gap in indigenous disadvantage [Internet]. Canberra: Council of Australian Governments; 2008. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.coag.gov.au/closing_the_gap_in_indigenous_disadvantage">https://www.coag.gov.au/closing_the_gap_in_indigenous_disadvantage</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2014 Sept 10].</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><collab>GBD 2013 Mortality and Causes of Death Collaborators</collab>. <article-title>Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990&#x02013;2013: a systematic analysis for the Global Burden of Disease Study 2013.</article-title>
<source>Lancet</source>. <year>2015</year>
<month>1</month>
<day>10</day>;<volume>385</volume>(<issue>9963</issue>):<fpage>117</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61682-2</pub-id><pub-id pub-id-type="pmid">25530442</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="book"><source>Regional action plan for viral hepatitis in the Western Pacific 2016&#x02013;2020.</source>
<publisher-loc>Manila</publisher-loc>: <publisher-name>World Health Organization Regional Office for the Western Pacific</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="web">Significant events in hepatitis B vaccination practice in Australia. Sydney: National Centre for Immunisation Research and Surveillance; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ncirs.edu.au/assets/provider_resources/history/Hepatitis-B-history-July-2015.pdf">http://www.ncirs.edu.au/assets/provider_resources/history/Hepatitis-B-history-July-2015.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 Nov 24].</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Graham</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Guy</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Cowie</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wand</surname>
<given-names>HC</given-names></string-name>, <string-name><surname>Donovan</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Akre</surname>
<given-names>SP</given-names></string-name>, <etal>et al.</etal>
<article-title>Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and meta-analysis.</article-title>
<source>BMC Infect Dis</source>. <year>2013</year>
<month>8</month>
<day>31</day>;<volume>13</volume>(<issue>1</issue>):<fpage>403</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-13-403</pub-id><pub-id pub-id-type="pmid">24004727</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>MacLachlan</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Allard</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Towell</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Cowie</surname>
<given-names>BC</given-names></string-name>. <article-title>The burden of chronic hepatitis B virus infection in Australia, 2011.</article-title>
<source>Aust N Z J Public Health</source>. <year>2013</year>
<month>10</month>;<volume>37</volume>(<issue>5</issue>):<fpage>416</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/1753-6405.12049</pub-id><pub-id pub-id-type="pmid">24090323</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="book">Contribution of chronic disease to the gap in mortality between Aboriginal and Torres Strait Islander people and other Australians [IHW cat. no. 48]. Canberra: Australian Institute of Health and Welfare; 2010.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Condon</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Armstrong</surname>
<given-names>BK</given-names></string-name>, <string-name><surname>Barnes</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cunningham</surname>
<given-names>J</given-names></string-name>. <article-title>Cancer in Indigenous Australians: a review.</article-title>
<source>Cancer Causes Control</source>. <year>2003</year>
<month>3</month>;<volume>14</volume>(<issue>2</issue>):<fpage>109</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1023/A:1023064400004</pub-id><pub-id pub-id-type="pmid">12749716</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Condon</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Barnes</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Cunningham</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Armstrong</surname>
<given-names>BK</given-names></string-name>. <article-title>Long-term trends in cancer mortality for Indigenous Australians in the Northern Territory.</article-title>
<source>Med J Aust</source>. <year>2004</year>
<month>5</month>
<day>17</day>;<volume>180</volume>(<issue>10</issue>):<fpage>504</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15139826</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="book"><source>National hepatitis B strategy 2010&#x02013;2013.</source>
<publisher-loc>Canberra</publisher-loc>: <publisher-name>Australian Government Department of Health and Ageing</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="web">National hepatitis B testing policy. Melbourne: National Hepatitis B Virus (HBV) Testing Policy Expert Reference Committee; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nrl.gov.au/CA25782200833499/Lookup/Resources%20%26%20Guidelines/$file/HBV_TESTING_POLICY_FORMATTED_V1.1_PRINT.pdf">http://www.nrl.gov.au/CA25782200833499/Lookup/Resources%20%26%20Guidelines/$file/HBV_TESTING_POLICY_FORMATTED_V1.1_PRINT.pdf</ext-link> [cited 2016 Aug 16].</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="book"><source>The Australian immunisation handbook.</source>
<edition>10th ed.</edition>
<publisher-loc>Canberra</publisher-loc>: <publisher-name>Australian Government Department of Health and Ageing</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>MacLachlan</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Allard</surname>
<given-names>NL</given-names></string-name>, <string-name><surname>Cowie</surname>
<given-names>BC</given-names></string-name>. <article-title>Disparities in hepatitis B vaccine funding in Australian jurisdictions: limiting access for priority populations.</article-title>
<source>Aust N Z J Public Health</source>. <year>2015</year>
<month>4</month>;<volume>39</volume>(<issue>2</issue>):<fpage>192</fpage>. <pub-id pub-id-type="doi">10.1111/1753-6405.12316</pub-id><pub-id pub-id-type="pmid">25827189</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Harrod</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Couzos</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Delaney-Thiele</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Dore</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Hammond</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Saunders</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Markers of hepatitis B infection and immunity in patients attending Aboriginal community controlled health services.</article-title>
<source>Med J Aust</source>. <year>2014</year>
<month>9</month>
<day>15</day>;<volume>201</volume>(<issue>6</issue>):<fpage>339</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.5694/mja14.00121</pub-id><pub-id pub-id-type="pmid">25222458</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="book"><source>National Aboriginal and Torres Strait Islander health survey 2004&#x02013;05.</source>
<publisher-loc>Canberra</publisher-loc>: <publisher-name>Australian Bureau of Statistics</publisher-name>; <year>2006</year>.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="book"><source>Aboriginal surveillance report of HIV, viral hepatitis, STIs.</source>
<publisher-loc>Sydney</publisher-loc>: <publisher-name>Kirby Institute, University of New South Wales</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="web">Introduction to the national notifiable diseases surveillance system [Internet]. Canberra: Australian Government Department of Health; 2016. Available from <ext-link ext-link-type="uri" xlink:href="http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-nndssintro.htm">http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-nndssintro.htm</ext-link> [cited 2016 Aug 12].</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="web">Hepatitis B (newly acquired) case definition. Canberra: Communicable Diseases Network Australia; 2004. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hepbnew.htm">http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hepbnew.htm</ext-link> [cited 2016 Aug 12]. </mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="web">Hepatitis B (unspecified) case definition. Canberra: Communicable Diseases Network Australia; 2004. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hepbun.htm">http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hepbun.htm</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2016 Aug 12]. </mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Naidu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Chiu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Habig</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lowbridge</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jayasinghe</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<article-title>Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006&#x02013;2010.</article-title>
<source>Commun Dis Intell Q Rep</source>. <year>2013</year>
<month>12</month>
<day>31</day>;<volume>37</volume>
<issue>Suppl</issue>:<fpage>S1</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">24410428</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Gardner</surname>
<given-names>ID</given-names></string-name>, <string-name><surname>Wan</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Simms</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Worswick</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Burrell</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Mathews</surname>
<given-names>JD</given-names></string-name>. <article-title>Hepatitis B virus markers in children and staff in Northern Territory schools.</article-title>
<source>Med J Aust</source>. <year>1992</year>
<month>5</month>
<day>4</day>;<volume>156</volume>(<issue>9</issue>):<fpage>638</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">1625617</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>O&#x02019;Sullivan</surname>
<given-names>BG</given-names></string-name>, <string-name><surname>Gidding</surname>
<given-names>HF</given-names></string-name>, <string-name><surname>Law</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kaldor</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Gilbert</surname>
<given-names>GL</given-names></string-name>, <string-name><surname>Dore</surname>
<given-names>GJ</given-names></string-name>. <article-title>Estimates of chronic hepatitis B virus infection in Australia, 2000.</article-title>
<source>Aust N Z J Public Health</source>. <year>2004</year>
<month>6</month>;<volume>28</volume>(<issue>3</issue>):<fpage>212</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1467-842X.2004.tb00697.x</pub-id><pub-id pub-id-type="pmid">15707165</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Burrell</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Cameron</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Hart</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Melbourne</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Beal</surname>
<given-names>RW</given-names></string-name>. <article-title>Hepatitis B reservoirs and attack rates in an Australian community. A basis for vaccination and crossinfection policies.</article-title>
<source>Med J Aust</source>. <year>1983</year>
<month>11</month>
<day>12</day>;<volume>2</volume>(<issue>10</issue>):<fpage>492</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">6226854</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Britton</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Parsons</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gallagher</surname>
<given-names>ND</given-names></string-name>, <string-name><surname>Cossart</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Burnett</surname>
<given-names>L</given-names></string-name>. <article-title>Risk factors associated with hepatitis B infection in antenatal patients.</article-title>
<source>Aust N Z J Med</source>. <year>1985</year>
<month>10</month>;<volume>15</volume>(<issue>5</issue>):<fpage>641</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">3867341</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Gill</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Bucens</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hatton</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Carey</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Quadros</surname>
<given-names>CF</given-names></string-name>. <article-title>Markers of hepatitis B virus infection in schoolchildren in the Kimberley, Western Australia.</article-title>
<source>Med J Aust</source>. <year>1990</year>
<month>7</month>
<day>2</day>;<volume>153</volume>(<issue>1</issue>):<fpage>34</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">2381358</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Menzies</surname>
<given-names>R</given-names></string-name>, <string-name><surname>McIntyre</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Beard</surname>
<given-names>F</given-names></string-name>. <article-title>Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002.</article-title>
<source>Commun Dis Intell Q Rep</source>. <year>2004</year>;<volume>28</volume>(<issue>2</issue>):<fpage>127</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">15460950</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Menzies</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Turnour</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chiu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>McIntyre</surname>
<given-names>P</given-names></string-name>. <article-title>Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006.</article-title>
<source>Commun Dis Intell Q Rep</source>. <year>2008</year>
<month>6</month>;<volume>32</volume>
<issue>Suppl</issue>:<fpage>S2</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">18711998</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Weinbaum</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Mast</surname>
<given-names>EE</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Finelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wasley</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>; <collab>Centers for Disease Control and Prevention (CDC)</collab>. <article-title>Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.</article-title>
<source>MMWR Recomm Rep</source>. <year>2008</year>
<month>9</month>
<day>19</day>;<volume>57</volume>
<issue>RR-8</issue>:<fpage>1</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">18802412</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="book"><string-name><surname>Van Damme</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Shouval</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wiersma</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zanetti</surname>
<given-names>A</given-names></string-name>. <chapter-title>Chapter 15</chapter-title>: <chapter-title>Hepatitis B vaccines.</chapter-title> In: <string-name><surname>Plotkin</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Orenstein</surname>
<given-names>WA</given-names></string-name>, <string-name><surname>Offit</surname>
<given-names>PA</given-names></string-name>, editors. <source>Vaccines.</source>
<edition>6th ed.</edition>
<publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Saunders Elsevier</publisher-name>; <year>2012</year> pp. <fpage>205</fpage>&#x02013;<lpage>34</lpage>.</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Halsey</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Moulton</surname>
<given-names>LH</given-names></string-name>, <string-name><surname>O&#x02019;Donovan</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Walcher</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Thoms</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Margolis</surname>
<given-names>HS</given-names></string-name>, <etal>et al.</etal>
<article-title>Hepatitis B vaccine administered to children and adolescents at yearly intervals.</article-title>
<source>Pediatrics</source>. <year>1999</year>
<month>6</month>;<volume>103</volume>(<issue>6 Pt 1</issue>):<fpage>1243</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1542/peds.103.6.1243</pub-id><pub-id pub-id-type="pmid">10353936</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Jilg</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Schmidt</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Deinhardt</surname>
<given-names>F</given-names></string-name>. <article-title>Vaccination against hepatitis B: comparison of three different vaccination schedules.</article-title>
<source>J Infect Dis</source>. <year>1989</year>
<month>11</month>;<volume>160</volume>(<issue>5</issue>):<fpage>766</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/160.5.766</pub-id><pub-id pub-id-type="pmid">2530289</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Cassidy</surname>
<given-names>WM</given-names></string-name>, <string-name><surname>Watson</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ioli</surname>
<given-names>VA</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bird</surname>
<given-names>S</given-names></string-name>, <string-name><surname>West</surname>
<given-names>DJ</given-names></string-name>. <article-title>A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory.</article-title>
<source>Pediatrics</source>. <year>2001</year>
<month>4</month>;<volume>107</volume>(<issue>4</issue>):<fpage>626</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1542/peds.107.4.626</pub-id><pub-id pub-id-type="pmid">11335734</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Schiff</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Sherwood</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Zeldis</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Krause</surname>
<given-names>DS</given-names></string-name>. <article-title>Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.</article-title>
<source>J Adolesc Health</source>. <year>1995</year>
<month>1</month>;<volume>16</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/1054-139X(94)00105-N</pub-id><pub-id pub-id-type="pmid">7742331</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Milne</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moyes</surname>
<given-names>CD</given-names></string-name>, <string-name><surname>Allwood</surname>
<given-names>GK</given-names></string-name>, <string-name><surname>Pearce</surname>
<given-names>NE</given-names></string-name>, <string-name><surname>Krugman</surname>
<given-names>S</given-names></string-name>. <article-title>Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.</article-title>
<source>N Z Med J</source>. <year>1988</year>
<month>2</month>
<day>24</day>;<volume>101</volume>(<issue>840</issue>):<fpage>67</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">2967940</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Andr&#x000e9;</surname>
<given-names>FE</given-names></string-name>. <article-title>Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine.</article-title>
<source>Am J Med</source>. <year>1989</year>
<month>9</month>
<day>4</day>;<volume>87</volume>(<issue>3</issue>) <supplement>3A</supplement>:<fpage>14S</fpage>&#x02013;<lpage>20S</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9343(89)90525-1</pub-id><pub-id pub-id-type="pmid">2528292</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Zajac</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>West</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>McAleer</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Scolnick</surname>
<given-names>EM</given-names></string-name>. <article-title>Overview of clinical studies with hepatitis B vaccine made by recombinant DNA.</article-title>
<source>J Infect</source>. <year>1986</year>
<month>7</month>;<volume>13</volume>
<issue>Suppl A</issue>:<fpage>39</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0163-4453(86)92668-X</pub-id><pub-id pub-id-type="pmid">2943814</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Alter</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Margolis</surname>
<given-names>HS</given-names></string-name>. <article-title>The emergence of hepatitis B as a sexually transmitted disease.</article-title>
<source>Med Clin North Am</source>. <year>1990</year>
<month>11</month>;<volume>74</volume>(<issue>6</issue>):<fpage>1529</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/S0025-7125(16)30493-X</pub-id><pub-id pub-id-type="pmid">2246951</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><string-name><surname>Aspinall</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kocks</surname>
<given-names>DJ</given-names></string-name>. <article-title>Immunogenicity of a low-cost hepatitis B vaccine in the South African Expanded Programme on Immunisation.</article-title>
<source>S Afr Med J</source>. <year>1998</year>
<month>1</month>;<volume>88</volume>(<issue>1</issue>):<fpage>36</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9539933</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><string-name><surname>Da Villa</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Pelliccia</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Peluso</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ricciardi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sepe</surname>
<given-names>A</given-names></string-name>. <article-title>Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine.</article-title>
<source>Res Virol</source>. <year>1997</year>
<season>Mar-Apr</season>;<volume>148</volume>(<issue>2</issue>):<fpage>109</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/S0923-2516(97)89893-7</pub-id><pub-id pub-id-type="pmid">9108609</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Greenberg</surname>
<given-names>DP</given-names></string-name>, <string-name><surname>Vadheim</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>VK</given-names></string-name>, <string-name><surname>Marcy</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Partridge</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Greene</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age.</article-title>
<source>Pediatr Infect Dis J</source>. <year>1996</year>
<month>7</month>;<volume>15</volume>(<issue>7</issue>):<fpage>590</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/00006454-199607000-00006</pub-id><pub-id pub-id-type="pmid">8823852</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>Hadler</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Margolis</surname>
<given-names>HS</given-names></string-name>. <article-title>Hepatitis B immunization: vaccine types, efficacy, and indications for immunization.</article-title>
<source>Curr Clin Top Infect Dis</source>. <year>1992</year>;<volume>12</volume>:<fpage>282</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">1386520</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Edmunds</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Medley</surname>
<given-names>GF</given-names></string-name>, <string-name><surname>Nokes</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Whittle</surname>
<given-names>HC</given-names></string-name>. <article-title>The influence of age on the development of the hepatitis B carrier state.</article-title>
<source>Proc Biol Sci</source>. <year>1993</year>
<month>8</month>
<day>23</day>;<volume>253</volume>(<issue>1337</issue>):<fpage>197</fpage>&#x02013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1098/rspb.1993.0102</pub-id><pub-id pub-id-type="pmid">8397416</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="book"><source>National blood-borne virus and sexually transmissible infections surveillance and monitoring report.</source>
<publisher-loc>Sydney</publisher-loc>: <publisher-name>Kirby Institute, University of New South Wales</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><collab>World Health Organization</collab>. <article-title>Hepatitis B vaccines.</article-title>
<source>Wkly Epidemiol Rec</source>. <year>2009</year>
<month>10</month>
<day>1</day>;<volume>84</volume>(<issue>40</issue>):<fpage>405</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">19817017</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>Goldstein</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Hadler</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Mast</surname>
<given-names>EE</given-names></string-name>, <string-name><surname>Margolis</surname>
<given-names>HS</given-names></string-name>. <article-title>A mathematical model to estimate global hepatitis B disease burden and vaccination impact.</article-title>
<source>Int J Epidemiol</source>. <year>2005</year>
<month>12</month>;<volume>34</volume>(<issue>6</issue>):<fpage>1329</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyi206</pub-id><pub-id pub-id-type="pmid">16249217</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="web">Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/">http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2016 Aug 12].</mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><string-name><surname>Hutton</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>So</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Brandeau</surname>
<given-names>ML</given-names></string-name>. <article-title>Cost&#x02013;effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.</article-title>
<source>Hepatology</source>. <year>2010</year>
<month>2</month>;<volume>51</volume>(<issue>2</issue>):<fpage>405</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1002/hep.23310</pub-id><pub-id pub-id-type="pmid">19839061</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>FZ</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Cui</surname>
<given-names>FQ</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>ZH</given-names></string-name>, <string-name><surname>Miao</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>An economic analysis of adult hepatitis B vaccination in China.</article-title>
<source>Vaccine</source>. <year>2015</year>
<month>11</month>
<day>27</day>;<volume>33</volume>(<issue>48</issue>):<fpage>6831</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.011</pub-id><pub-id pub-id-type="pmid">26384449</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="book"><source>Housing circumstances of indigenous households: tenure and overcrowding.</source>
<publisher-loc>Canberra</publisher-loc>: <publisher-name>Australian Institute of Health and Welfare</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><string-name><surname>Rowe</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Cowie</surname>
<given-names>BC</given-names></string-name>. <article-title>Using data linkage to improve the completeness of Aboriginal and Torres Strait Islander status in communicable disease notifications in Victoria.</article-title>
<source>Aust N Z J Public Health</source>. <year>2016</year>
<month>4</month>;<volume>40</volume>(<issue>2</issue>):<fpage>148</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1111/1753-6405.12434</pub-id><pub-id pub-id-type="pmid">26337430</pub-id></mixed-citation></ref></ref-list></back></article>